Patents by Inventor Bander Alshemary

Bander Alshemary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11970464
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11964947
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: April 23, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Multi-target drug candidates for the treatment of triple-negative breast cancer
    Patent number: 11891363
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: February 6, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary